Drug Profile
AZD 1704
Alternative Names: AZD1704Latest Information Update: 17 Feb 2009
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Analgesics
- Mechanism of Action Cannabinoid receptor CB1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 29 Jan 2009 Discontinued - Phase-I for Pain in United Kingdom (PO)